Salarius Pharma (SLRX): Price-to-Projected Revenue Ratio
Salarius Pharmaceuticals develops targeted therapies for rare tumors utilizing a flexible outsourcing model for production and research. The expected price-to-sales ratio reflects market expectations, where 20.40 determines this specific parameter level. However, the lack of profitability and a reliance on a narrow pipeline of experimental drugs create significant risks to business continuity.
Analytical breakdowns for Salarius Pharmaceuticals
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Capital Salarius Pharmaceuticals|SLRX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio salariuspharma.com|SLRX - Company Aggregate Debts|Debt to Book Capitalization Ratio Salarius|SLRX - Long-Term Debt Volume|Company Current Liabilities Salarius Pharmaceuticals|Quick Liquidity salariuspharma.com
- financial results and valuation multiples details:
SLRX - Profit After Tax|Projected Future Earnings Salarius Pharmaceuticals|SLRX - Company Value to Net Income|Forward P/E Multiple Salarius Pharma|SLRX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Salarius Pharmaceuticals Inc|SLRX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Salarius Pharmaceuticals|SLRX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth salariuspharma.com|SLRX - Earnings growth in current year|Earnings growth forecast for next year Salarius Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:SLRX (Salarius Pharma)
Forward P/S measures the market value of a business relative to expected revenue, allowing for an assessment of an asset's margin of safety through the dynamics of future cash flows. By analyzing the forward P/S of the firm, an investor determines the degree of stock overvaluation, which is critical for Salarius Pharmaceuticals (SLRX), where liquidity risks and R&D costs for targeted inhibitors are already priced into the current exchange rate.
Analysis of competing companies
Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Renovaro - Forward P/S Multiple|Mural Oncology (MURA) - Forward Price-to-Revenue Multiple|KAPA: Forward P/S Multiple|OKUR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CytoMed Therapeutics Limited|CRIS: Forward Price to Sales|Forward P/S Multiple APLM|Forward P/S Multiple tharimmune.com (THAR)|Advanced Biomed Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales GNPX|Calidi Biotherapeutics, Inc. - Forward P/S Multiple|Sunshine Biopharma (SBFM) - Forward Price-to-Revenue Multiple|XBIO: Forward P/S Multiple|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple
